Indaptus Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
| For the three months ended March 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| Cash flows from operating activities: | |||
| Net loss | $(4,532,430) | $(3,806,677) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | - | 735 | |
| Stock-based compensation | 240,891 | 774,691 | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current and non-current assets | 7,346 | 332,125 | |
| Accounts payable and other current liabilities | (762,338) | (1,237,499) | |
| Operating lease right-of-use asset and liability, net | (596) | 163 | |
| Net cash used in operating activities | (5,047,127) | (3,936,462) | |
| Cash flows from financing activities: | |||
| Proceeds from issuance of shares of common stock and warrants | 3,482,650 | 336,044 | |
| Issuance costs | (331,255) | (19,997) | |
| Net cash provided by financing activities | 3,151,395 | 316,047 | |
| Net decrease in cash and cash equivalents | (1,895,732) | (3,620,415) | |
| Cash and cash equivalents at beginning of period | 5,786,753 | 13,362,053 | |
| Cash and cash equivalents at end of period | $3,891,021 | $9,741,638 | |
| Noncash investing and financing activities | |||
| Transaction costs in accounts payable and other current liabilities | $5,000 | $ | - |
| Issuance of commitment shares | $3,059 | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.